One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.

In multivariable analysis, risk factors for arterial thrombosis-free survival were age ≥60 years (HR 2.0; p < 0.001) and JAK2 mutation (HR 1.3; p = 0.02) with borderline significance for male gender ( p = 0.08) and cardiovascular risk factors ( p = 0.08); for venous thrombosis-free survival, JAK2 mutation (HR 1.9; p = 0.03) with borderline significance for venous thrombosis history ( p = 0.07); for overall survival, older age ( p < 0.001), male gender (HR 1.9; p < 0.001), absol

also in 7,017 other papers